[CAS NO. 29031-19-4] Glucosamine sulfate
PRODUCTS SPECIFICATIONS [29031-19-4]
DESCRIPTION [29031-19-4]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 277.25 |
| Molecular Formula | C6H15NO9S |
| SMILES | O=C[C@H](N)[C@H]([C@@H]([C@@H](CO)O)O)O.O=S(O)(O)=O |
3 Publications Citing Use of MCE
Summary
Glucosamine sulfate (D-Glucosamine sulfate) is an amino sugar and a prominent precursor in the biochemical synthesis of glycosylated proteins and lipids, is used as a dietary supplement. Glucosamine sulfate also is a natural constituent of glycosaminoglycans in the cartilage matrix and synovial fluid, which when administered exogenously, exerts pharmacological effects on osteoarthritic cartilage and chondrocytes [1] .
IC50 & Target
|
Human Endogenous Metabolite |
In Vitro
Glucosamine sulfate (D-Glucosamine sulfate) exhibits dose-dependent DPPH antioxidant activity
[2]
.
Glucosamine sulfate treatment of Short-term (4 h) inhibits HIF-1α at the protein level, decreases phosphorylation of p70S6K and S6, translation-related proteins
[3]
.
Glucosamine sulfate significantly decreases renal expression of α-smooth muscle actin, collagen I, and fibronectin in the obstructed kidneys and TGF-β1-treated renal cells
[4]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00110474 | Rottapharm |
Knee Osteoarthritis
|
May 2000 | Phase 3 |
| NCT00377286 | University of Pittsburgh |
Osteoarthritis
|
September 2006 | Not Applicable |
| NCT02306083 | Shahid Beheshti University of Medical Sciences |
Intraocular Pressure Changes After Glucosamine Sulfate Consumption.
|
July 2014 | Phase 3 |
| NCT00032890 | US Department of Veterans Affairs|National Center for Complementary and Integrative Health (NCCIH)|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|VA Office of Research and Development |
Osteoarthritis
|
April 2000 | Phase 3 |
| NCT02448199 | Zodiac Produtos Farmaceuticos S.A.|Eurotrials Brasil Consultores Cientificos Ltda |
Osteoarthritis
|
July 2015 | Phase 3 |
| NCT04706416 | Quantinosis.ai LLC |
Coronavirus|Covid19
|
November 14, 2020 | Phase 1 |
| NCT05212259 | Vedic Lifesciences Pvt. Ltd. |
Joint Pain
|
July 31, 2022 | Not Applicable |
| NCT00404079 | Ullevaal University Hospital|Stiftelsen Helse og Rehabilitering|Oslo University Hospital |
Low Back Pain
|
December 2006 | Phase 4 |
| NCT00955552 | Eurofarma Laboratorios S.A. |
Osteoarthritis of the Knee
|
April 2010 | Phase 3 |
| NCT00251069 | Slidgigtinstituttet|Pharma Nord |
Osteoarthritis
|
April 2005 | Phase 4 |
| NCT01682694 | Fred Hutchinson Cancer Center |
Inflammation
|
September 2012 | Not Applicable |
| NCT05237596 | University of Siena |
Erosive Osteoarthritis of the Hand
|
January 7, 2021 | |
| NCT00317655 | Ferrosan AS |
Back Pain
|
April 2006 | Phase 4 |
| NCT00860873 | Azidus Brasil |
Osteoarthrosis
|
October 2009 | Phase 3 |
| NCT00065377 | National Center for Complementary and Integrative Health (NCCIH)|National Institutes of Health Clinical Center (CC) |
Obesity|Insulin Resistance
|
July 2003 | Phase 1 |
| NCT02167516 | The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine |
Knee Osteoarthritis
|
October 2014 | Not Applicable |
| NCT03716115 | Queen Mary University of London |
Severe Acute Malnutrition
|
May 4, 2020 | Phase 2 |
| NCT00691678 | Dawn L. Hershman|Columbia University |
Breast Cancer|Joint Pain
|
October 2008 | Phase 2 |
| NCT02830919 | Eurofarma Laboratorios S.A. |
Osteoarthritis of Knee
|
December 5, 2016 | Phase 3 |
| NCT02214095 | Ain Shams University |
Chronic Periodontitis
|
January 2012 | Early Phase 1 |
| NCT01172249 | Mantecorp Industria Quimica e Farmaceutica Ltd. |
Osteoarthritis, Knee
|
Phase 3 | |
| NCT03743896 | Lynk Biotechnologies Pte Ltd|T&T Family Health Clinic and Surgery, Singapore|Temasek Polytechnic School of Applied Science, Singapore |
Osteoarthritis, Knee
|
May 18, 2016 | Phase 4 |
| NCT01293305 | Azidus Brasil |
Osteoarthritis
|
November 2011 | Phase 3 |
| NCT03827161 | Fred Hutchinson Cancer Center |
Healthy Subject|Overweight
|
August 1, 2017 | Phase 1 |
| NCT05321836 | Muhammad salman, PT|Neuro Counsel Hospital, Pakistan |
Knee Osteoarthritis
|
July 26, 2021 | Not Applicable |
| NCT02858297 | Ain Shams University |
Oral Lichen Planus
|
May 2015 | Phase 4 |
| NCT04665804 | Foundation University Islamabad |
Knee Osteoarthritis
|
June 10, 2020 | Not Applicable |
| NCT05474586 | Vedic Lifesciences Pvt. Ltd. |
Osteoarthritis, Knee
|
August 8, 2022 | Not Applicable |
| NCT04470336 | Vedic Lifesciences Pvt. Ltd. |
Knee Osteoarthritis
|
July 9, 2020 | Not Applicable |
| NCT02604381 | KGK Science Inc.|Joint Health Wellness Group, LLC. |
Osteoarthritis of the Knee
|
November 2015 | Phase 2 |
| NCT03201276 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
Knee Osteoarthritis
|
July 2, 2017 | |
| NCT01906801 | Ramathibodi Hospital |
Osteoarthritis|Glucosamine|Diacerein
|
July 2013 | Phase 4 |
| NCT01074476 | University of British Columbia |
Knee Osteoarthritis
|
June 2015 | Not Applicable |
| NCT00086229 | National Center for Complementary and Integrative Health (NCCIH) |
Osteoarthritis
|
April 2004 | Not Applicable |
| NCT03963323 | Fred Hutchinson Cancer Center |
Healthy Subject
|
May 11, 2018 | Phase 1 |
| NCT04121533 | Intermountain Health Care, Inc.|USANA Health Sciences |
Osteoarthritis, Knee|Vitamin D Supplementation
|
July 28, 2011 | Not Applicable |
| NCT02010918 | Ache Laboratorios Farmaceuticos S.A. |
Knee Osteoarthritis
|
February 2009 | Phase 3 |
| NCT03911570 | University of Siena |
Hand Osteoarthritis
|
September 1, 2018 | |
| NCT00833157 | Bispebjerg Hospital|Lund University|The Danish Rheumatism Association|Ministry of the Interior and Health, Denmark |
Osteoarthritis of the Knee
|
February 2005 | Phase 1 |
| NCT03936192 | Eurofarma Laboratorios S.A. |
Knee Osteoarthritis
|
January 2019 | Phase 3 |
| NCT00513422 | University of Sydney|National Health and Medical Research Council, Australia |
Osteoarthritis, Knee
|
October 2007 | Phase 4 |
| NCT03717714 | Vietstar Biomedical Research |
Osteoarthritis of the Knee
|
April 1, 2017 | Not Applicable |
| NCT00805519 | Ardabil University of Medical Sciences |
Osteoarthritis of the Knee
|
February 2009 | Phase 4 |
| NCT01789151 | University of Sydney|AbbVie |
Rheumatoid Arthritis|Ankylosing Spondylitis
|
||
| NCT03209895 | U.S. Nutraceuticals, LLC |
Joint Pain
|
October 8, 2010 | Not Applicable |
| NCT03106584 | University College Dublin|Marigot Ltd. |
Knee Osteoarthritis
|
May 1, 2017 | Not Applicable |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H 2 O : 125 mg/mL ( 450.86 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.6069 mL | 18.0343 mL | 36.0685 mL |
| 5 mM | 0.7214 mL | 3.6069 mL | 7.2137 mL |
| 10 mM | 0.3607 mL | 1.8034 mL | 3.6069 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (360.69 mM); Clear solution; Need ultrasonic
References
- [1] Bruyère O, et al. Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S12-7.
- [2] Jamialahmadi K, et al. Protective effects of glucosamine hydrochloride against free radical-induced erythrocytes damage. Environ Toxicol Pharmacol. 2014 Jul;38(1):212-9.
- [3] Jo JR, et al. Short-term treatment with glucosamine hydrochloride specifically downregulates hypoxia-inducible factor-1α at the protein level in YD-8 human tongue cancer cells. Int J Oncol. 2014 May;44(5):1699-706.
- [4] Park J, et al. Glucosamine hydrochloride exerts a protective effect against unilateral ureteral obstruction-induced renal fibrosis by attenuating TGF-β signaling. J Mol Med (Berl). 2013 Nov;91(11):1273-84.
Synonyms